(IN BRIEF) Boehringer Ingelheim has initiated the THULITE Phase II trial (NCT06962839) to assess BI 1815368, a novel oral agent for diabetic macular edema (DME). Affecting more than 21 million people globally, DME is typically managed by frequent eye injections, … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged at-home treatment, BI 1815368, BI 764524, biopharmaceutical research, Boehringer Ingelheim, Charles C. Wykoff, clinical trial NCT06962839, CRIMSON trial, Dario Madani, diabetic macular edema, diabetic retinal disease, DME, intravitreal injections, macular edema, oral therapy, Patrick Bussfeld, PRO RETINA, retinal vascular hyperpermeability, Sema3A antibody, THULITE Phase II, vision loss
In the YOSEMITE and RHINE studies in diabetic macular edema, at least 60% of eligible Vabysmo patients could extend treatment to every four months at two years, compared to 50% at year one Almost 80% of eligible Vabysmo patients could extend treatment to every … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Switzerland
Tagged Angiogenesis, bispecific antibody, diabetic macular edema, DME, Exudation and Degeneration 2022, eye injections, eye medicine, Levi Garraway M.D. Ph.D., Neovascular AMD, ranibizumab, retinal conditions, RHINE, Roche, Susvimo, Susvimo Archway, Vabysmo, vision loss, YOSEMITE
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?